News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Phase II (World)
Ablynx (ABLYF) Opens Recruitment For First-In-Infant Phase 2a Study With Its Anti-Rsv Nanobody, ALX-0171 12/17/2014
Pivotal Therapeutics Inc. Release: VASCAZEN POMEGA Phase 2a Trial Protocol Cleared Clinical Evaluation By French FDA 12/17/2014
First Patient Treated In Mapi Pharma's Phase 2a Clinical Trial Of GA Depot For Relapsing Remitting Multiple Sclerosis (RRMS) 12/17/2014
Poxel Announces Positive Top Line Results For Its Antidiabetic Agent Imeglimin In A Phase 2b Dose-Ranging Trial 12/17/2014
GENFIT Corp. (ALGFT): Gft505 Treatment Prevents Evolution To Cirrhosis 12/16/2014
VBL Therapeutics (VBLX) Announces Last Patient Out In Phase 2 Clinical Studies Of VB-201 In Psoriasis And Ulcerative Colitis 12/15/2014
Can-Fite BioPharma (CFBI) Release: Second Part Of The Glaucoma Phase 2 Study Has Been Approved In A European Country 12/15/2014
Merck & Co. (MRK),NewLink Genetics Ebola Trial Suspended After Patients Complain Of Joint Pain 12/12/2014
TWi Pharmaceuticals, Inc. Receives Approval Of Protocol For Its Drug Ac-201 Controlled-Release Tablet, Phase 2 Clinical Trial In Both The United States And Taiwan 12/12/2014
Kamada Ltd. (KMDA) Announces Positive Interim Results From Phase 1/2 Clinical Study Of Its Human Alpha-1 Antitrypsin To Treat Graft-Versus-Host Disease Presented At American Society of Hematology Annual Meeting 12/11/2014
Merck Announces Positive Data Investigating The Use Of Pembrolizumab In Patients With Advanced Triple-Negative Breast Cancer At 2014 San Antonio Breast Cancer Symposium 12/10/2014
Kiadis Pharma Presents Positive Data From A Pre Specified Interim Analysis Of The Phase 2 Clinical Program With Its Lead Product ATIR 12/9/2014
MorphoSys AG And Xencor Publish Final Results From Phase 1/2a Trial Of MOR208 (Xmab5574) In CLL/SLL At Xencor Annual Meeting 12/8/2014
Generon (Shanghai) Corporation Ltd. Presents The Global Phase 2 Study Results For F-627 (Benegrastim) At American Society of Hematology 56th Annual Meeting At San Francisco 12/8/2014
QLT Inc. (QLTI) Announces Results From Proof-of-Concept Trial With Oral Synthetic Cis-Retinoid (QLT091001) In Adult Subjects With Impaired Dark Adaptation And/Or Impaired Low Luminance Vision 12/5/2014
Genmab A/S (GEN.CO) Announces Phase 2 Study Of Daratumumab In Non-Hodgkin's Lymphomas 12/4/2014
Karyopharm Therapeutics (KPTI) Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission (EC) 12/1/2014
Takeda Pharmaceuticals’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation By U.S. FDA For Relapsed Or Refractory Systemic Light-Chain Amyloidosis 12/1/2014
Dynavax Technologies Corporation (DVAX) Regains Full Rights To Investigational TLR 7/9 Inhibitor DV1179 Following Expiration Of Collaboration With GlaxoSmithKline (GSK) 12/1/2014
Novartis AG (NVS) Fires Scientist Who Falsified Data In 6 Research Papers 12/1/2014
Milestone Pharmaceuticals Announces Positive Phase 1 Data For MSP-2017; Supports Advancement Into Phase 2 In PSVT Patients 11/24/2014
Transition Therapeutics Inc. (TTH.TO)' ELND005 Showed No Prolongation Of QT Interval 11/24/2014
Clementia Pharmaceuticals Receives European Medicines Agency Orphan Medicinal Product Designation For Palovarotene For The Treatment Of Fibrodysplasia Ossificans Progressiva 11/21/2014
Clovis Oncology (CLVS) Release: Initial Data From Ongoing Phase 2 ARIEL2 Study Of Rucaparib In Ovarian Cancer Demonstrate Encouraging Clinical Activity And Safety In Both BRCA Mutant And Brcaness Patients 11/20/2014
Transition Therapeutics Inc. (TTH.TO) Announces Results From ELND005 Clinical Study In Adults With Down Syndrome 11/20/2014
Autifony Therapeutics Announces Initiation Of Phase 2a Study For First-In-Class Drug To Treat Tinnitus 11/20/2014
Cynapsus Therapeutics (CYNAF) Announces Positive Top-Line Results From CTH-105 Phase 2 Study Of APL-130277 For The Treatment Of OFF Episodes In Patients With Parkinson's Disease 11/19/2014
Bio Blast Pharma Receives Orphan Drug Designation From U.S. FDA For Cabaletta For The Treatment Of Spinocerebellar Ataxia Type 3 11/19/2014
BIND Therapeutics (BIND) Presents Positive Phase 2 Results Highlighting Potential Of BIND-014 As Novel Anti-Cancer Treatment At Q3W Dosing Schedule For Patients With Non-Small Cell Lung Cancer At 26th EORTC-NCI-AACR Annual Symposium 11/19/2014
Tokai Pharmaceuticals (TKAI) Presents Updated Interim Galeterone ARMOR2 Data Showing Activity In Patients With Castration-Resistant Prostate Cancer (CRPC) Including Those Showing A Variant Form Of Prostate Cancer Resistant To Hormone Therapy 11/19/2014
ObsEva Announces The Initiation Of A Pivotal Phase 2 Study To Evaluate OBE001 For Improving Embryo Implantation And Clinical Pregnancy Rate In Women Undergoing IVF/ICSI 11/18/2014
Merck & Co. (MRK) Announces Positive Study Investigating The Use Of KEYTRUDA® (pembrolizumab) Compared To Chemotherapy In Patients With Ipilimumab-Refractory Advanced Melanoma 11/17/2014
Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 11/17/2014
Mesoblast Limited (MSB.AX)'s Phase 2 Trial Results In Chronic Low Back Pain Presented At North American Spine Society Annual Meeting 11/13/2014
Galmed Pharmaceuticals Announces First Administration Of Aramchol In Its Phase 2a Trial For The Treatment Of Cholesterol Gallstones 11/13/2014
GenKyoTex S.A. Completes Enrollment Into Phase 2 Trial Of NOX1&4 Inhibitor GKT137831 In Diabetic Nephropathy 11/13/2014
Galapagos NV (GLPG.BR) Completes Recruitment For Darwin 1 Study With GLPG0634 (Filgotinib) In RA 11/12/2014
AB Science (AB.PA): The Data And Safety Monitoring Board Recommends The Continuation Of The Phase 2 Study With Masitinib In Advanced Hepatocellular Carcinoma 11/12/2014
CASI Pharmaceuticals  (ENMD) Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Soft Tissue Sarcoma 11/12/2014
Enzymotec Initiates Clinical Study Of Vayarin® In Adult ADHD 11/11/2014
Prima Biomed (PRR.AX) Release: CVac Demonstrates Overall Survival Benefit In Second Remission Ovarian Cancer 11/6/2014
D-Pharm Ltd. Reports First Results From Its Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With tPA 11/4/2014
BioLineRx Ltd. Files Protocol Amendment To Phase 2 Study For AML Treatment Based On Encouraging Efficacy And Strong Safety Profile 11/3/2014
Onxeo: Positive Phase 2 Preliminary Results Of Validive® For The Prevention Of Severe Oral Mucositis In Head And Neck Cancer Patients 10/31/2014
Kiadis Pharma's Lead Product ATIR™ Granted Orphan Drug Designation By European Medicines Agency For The Treatment Of Acute Myeloid Leukemia 10/30/2014
Apogenix- Positive Results From APG101 Phase 2 Clinical Trial Published In Clinical Cancer Research 10/28/2014
Moberg Pharma AB (Formerly known as Moberg Derma): First Patient Included In Phase 2 Study Of BUPI, A Novel Topical Formulation For Treatment Of Oral Pain 10/28/2014
TxCell Achieves Positive Results For Col-Treg In A Model Of Autoimmune Uveitis 10/28/2014
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/28/2014
Generex Biotechnology Corporation (GNBT) Announces Presentations Correlating Immunological Response With Reduced Recurrence In Phase 2 Study Of AE37 Breast Cancer Vaccine In Patients At The American College of Surgeons 10/27/2014
Clementia Announces Open-Label Phase 2 Extension Study Of Palovarotene In Patients With Fibrodysplasia Ossificans Progressiva 10/27/2014
Ablynx (ABLYF)'s Ant-Il-6R Nanobody Partnered With AbbVie (ABBV) Demonstrates A Bioavailability Of More Than 80% After Subcutaneous Injection 10/23/2014
Oramed Pharmaceuticals Inc. (ORMP) Reports Positive Top-Line Data From U.S. Phase 2a Trial With Oral Insulin In Type 1 Diabetes 10/22/2014
Nuvo Research Inc. (NRI.TO) Completes WF10™ U.S. Market Study For Treatment Of Refractory Allergies 10/22/2014
GW Pharmaceuticals Announces Epidiolex® Receives Orphan Designation From European Medicines Agency For The Treatment Of Dravet Syndrome 10/22/2014
Maxwell Biotech Portfolio Company Hepatera Announces Proof-Of-Concept Clinical Results With Myrcludex B, A Novel Entry Inhibitor For Treatment Of Chronic Hepatitis B And Delta 10/21/2014
TWi Biotechnology Receives Orphan Drug Designation For Its Lead Drug Candidate AC-201 In United States 10/21/2014
Norgine Release: Positive Results From Phase 2 Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 10/20/2014
Nanobiotix Receives First Approval To Start Phase 2/3 Registration Trial In Soft Tissue Sarcoma In Europe 10/16/2014
Cannabis Biopharma GW Pharmaceuticals Sees Disappointing Data For Colitis Drug 10/15/2014
Tekmira (TKMR)'s Partner Reports Positive Clinical Data For LNP-Enabled Patisiran 10/15/2014
Scancell Release: AGM Research And Development Update Highlights Progress In Both SCIB1 Clinical Trial And Moditope® Platform 10/14/2014
EU-Funded Consortium Led By immatics biotechnologies GmbH And BioNTech To Advance A Novel Class Of Fully Personalized Therapeutic Cancer Vaccines Into Clinical Trials For Brain Cancer 10/14/2014
Medivir AB (MVRBF): Phase 2 IMPACT Study Initiated To Evaluate Simeprevir In Combination With Sofosbuvir And Daclatasvir To Treat Genotype 1 And 4 Hepatitis C Patients 10/10/2014
Biotron Limited (BIT:AU) Release: BIT225 Trial Results Show Effective Cure Of Hepatitis C 10/10/2014
Galapagos NV (GLPG.BR) Presents Novel Cystic Fibrosis Combination Therapy At NACFC 10/9/2014
BrainStorm Cell Therapeutics Inc. Nabs FDA Fast-Track Status For ALS Stem Cell Therapy 10/8/2014
Medgenics, Inc. To Present Initial Clinical Data From MDGN-201 Study At European Society Of Gene And Cell Therapy Congress 10/7/2014
Foamix Pharmaceuticals, Ltd. (FOMX) Announces Initiation Of Phase 2 Trial With FDX104 In Chemotherapy Induced Rash 10/6/2014
Collaboration With Dr. Stephen Waxman Of Yale University To Evaluate Pharmacology Of Nav1.7 Mutations In Chronic Pain Disorders 10/6/2014
Horizon Pharma plc.  (HZNP) Receives Orphan-Drug Designation For ACTIMMUNE(R) (Interferon gamma-1b) In Friedreich's Ataxia 10/6/2014
Galderma Initiates U.S. Study Of Novel Muscle Relaxant For Aesthetic Dermatology And Cosmetic Surgery 10/6/2014
Merrimack Pharmaceuticals Inc. (MACK) Presents Additional Phase 2 Biomarker Data Further Strengthening The Finding That MM-121 Increases Progression Free Survival In Patients With Biomarker Positive Metastatic Breast Cancer 9/30/2014
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN)'s Dupilumab Successful In Phase 2 Study 9/30/2014
Bionomics Limited (BNO.AX) Presents BNC105 Phase 2 Renal Cancer Trial Biomarker Data 9/29/2014
Viralytics Ltd (VLA.AX) Release: Updated Positive Data From Phase 2 Trial Of CAVATAK In Late-Stage Melanoma 9/29/2014
NOXXON Pharma AG Spiegelmer® Receives FDA Orphan Drug 9/23/2014
BioBlast Pharma (ORPN) Announces Initiation Of Its Canadian OPMD Clinical Study Center At McGill University, Montreal 9/22/2014
ProSensa Holding N.V. (RNA) Announces Commencement Of Re-Dosing Of Drisapersen In North America In Patients With Duchenne Muscular Dystrophy 9/18/2014
Immune Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial In Ulcerative Colitis 9/18/2014
Galapagos NV (GLPG.BR) Reports High Participation Rate In Long Term Extension Study With GLPG0634 In RA Patients 9/18/2014
BioBlast Pharma (ORPN) Announces Preclinical And Clinical Pharmacokinetic Results With Cabaletta, Interim Safety Results From Phase 2/3 HOPEMD Study In OPMD 9/17/2014
Glenmark Pharmaceuticals's TRPA1 Antagonist 'GRC 17536' Shows Positive Data In A Proof Of Concept Study 9/17/2014
Amarantus BioSciences, Inc. Provides Program Update On Phase 2b Eltoprazine For Parkinson's Disease And Adult ADHD 9/17/2014
NovaBiotics Ltd Receives Orphan Drug Status From FDA For Lynovex® For The Treatment Of Cystic Fibrosis 9/16/2014
Ascendis Pharma A/S Announces Positive Interim Results From A Phase 2 Pediatric Study Of Once-Weekly Transcon Growth Hormone For The Treatment Of Growth Hormone Deficiency 9/16/2014
Prosonix Confirms The Potential Of Its Multi-Component Particle™ Technology For Developing Novel Inhaled Dual And Triple Combination Therapies For Respiratory Diseases 9/11/2014
Amarantus BioSciences, Inc. Announces Positive MANF Ocular Toxicology Data 9/9/2014
AstraZeneca PLC (AZN)’s Phase 2 Lung Drug Data Gives Mixed Messages 9/9/2014
ProSensa Holding N.V. (RNA) Announces Lancet Neurology Publication Of An Exploratory Phase 2 Study (DEMAND II) Demonstrating Efficacy And Safety Of Drisapersen In Patients With Duchenne Muscular Dystrophy 9/8/2014
European Medicines Agency Accepts TiGenix Pediatric Investigation Plan For Cx601 9/8/2014
Kamada Ltd. (KMDA) Reports Final Results From Phase 2/3 Clinical Trial Of Inhaled Alpha-1 Antitrypsin To Treat Alpha-1 Antitrypsin Deficiency 9/4/2014
Oncolytics Biotech Inc. (ONC.TO) Neuroderm Announces Start Of Phase 2a Study Of Continuous Subcutaneous Liquid Levodopa/Carbidopa Administration For Patients With Severe Parkinson's Disease 9/3/2014
GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach To Treat Multiple Sclerosis 9/3/2014
Alcobra (ADHD) Announces Enrollment Of First Patient In Phase 2b Clinical Trial Of MDX In Adolescents With ADHD 9/2/2014
AstraZeneca PLC (AZN) Pops On Possibility Of Another Pfizer (PFE) Bid; Start Of New Cancer Trial 9/2/2014
ERYtech Pharma Announces Second Positive DSMB Review Of Its Phase 2b Study In Acute Myeloid Leukemia 8/27/2014
Alcobra (ADHD) Announces Enrollment Of First Patient In Phase 2b Clinical Trial Of MDX In Fragile X Syndrome 8/19/2014
NeuroVive Pharmaceutical ABl: Enrollment To Phase 2 Study On NeuroSTAT® Continues 8/15/2014
Austrianova Release: Human Clinical Trials Confirm Safety And Efficacy Of Encapsulated Cell Treatment For Pancreatic Cancer 8/15/2014
Phosphagenics Limited (POH.AX) Completes First IND Enabling Study For TPM(R) / Oxymorphone Patch 8/11/2014
Concordia Healthcare Corp (CXR.TO) Announces First Patients Enrolled In Phase 2 Clinical Trial Using Photodynamic Therapy With PHOTOFRIN(R) For Patients With Mesothelioma 8/11/2014
Alcobra (ADHD) Releases New Neuroimaging Data Supporting Pro-Cognitive Effects Of MDX 8/8/2014
Celsus Therapeutics (CLTX) Announces First Patient Enrolled In Phase 2 Trial Of MRX-6 In Pediatric Atopic Dermatitis 8/6/2014
Amarantus BioSciences, Inc. Announces Positive Top-Line Interim Clinical Data For Alzheimer's Blood Diagnostic Lympro Test® 8/4/2014
Amarantus BioSciences, Inc. Amends LymPro LP-002 Clinical Protocol to Report Interim Data at Presentation 7/30/2014
BioTie Therapies Corp. Updates Outlook On Tozadenant And SYN120 7/30/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1103 Acromegaly Phase 2 Trial Dosing Completed 7/29/2014
MorphoSys AG Provides Update On The Company's Proprietary Drug Portfolio 7/28/2014
Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 7/28/2014
Retroscreen Conducts Landmark hVIVO Human Challenge Model Study Of AL-8176 In RSV For Alios BioPharma 7/28/2014
GANYMED Pharmaceuticals AG Completes Recruitment For Randomized Phase 2 FAST Trial Of IMAB362 For Gastroesophageal Cancer 7/22/2014
"MetaMax" LLC Maxwell Biotech Venture Fund's Portfolio Company MetaMax Announces Enrollment Of First Patients In Phase 1/2a Clinical Trial Of Its Lead Anticancer Drug MM-D37K 7/21/2014
Can-Fite BioPharma (CFBI) CEO To Deliver Scientific Presentation And Serve On Expert Panel At Purines 2014 In Bonn, Germany On July 23-27, 2014 7/21/2014
CASI Pharmaceuticals  (ENMD) To Start China Trial Of Cancer Drug 7/21/2014
Amarantus BioSciences, Inc. Discusses New Independent Peer-Reviewed Research Papers On MANF 7/18/2014
Roche (RHHBY) Alzheimer's Drug Crenezumab Fails Main Goals In Phase 2 Study 7/17/2014
Consortium Of Food Allergy Research Completes Recruitment Of National Institutes of Health (NIH)-Sponsored Cofar6 Phase 2Trial With DBV Technologies's Viaskin® Peanut In Treatment Of Peanut Allergy 7/17/2014
DBV Technologies Completes Last "Food Challenge" Visit Of Last Peanut-Allergic Patient In VIPES Phase 2b Clinical Study 7/17/2014
BioTie Therapies Corp. Selects Bracket's CDR System™ For Phase 2 Trial Of Treatment Of Parkinson's Disease 7/16/2014
Amarillo Biosciences (AMAR) Announces Positive Analytical Performance Data Poster Presentation For Lympro Test At AAIC 2014 7/14/2014
Astellas Pharma Inc. (ALPMY) Details Pipeline Progress At R&D Meeting 7/11/2014
Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA (Netupitant 300 Mg + Oral Palonosetron 0.50 Mg), Will Be Published In The Annals Of Oncology 7/10/2014
Pluristem Therapeutics (PSTI) Initiates South Korean Arm of Multinational Phase 2 Intermittent Claudication Trial 7/8/2014
BioTie Therapies Corp.: Tozadenant Phase 2b Parkinson's Disease Study Published In Lancet Neurology 7/8/2014
Dignity Sciences Release: DS107E-02 - Positive Phase 2 Results In Atopic Dermatitis 7/8/2014
Pharma Two B Ltd. Expands List Of Clinical Sites Enrolling For Phase IIb Study Of P2B001 For PD To 25 7/2/2014
Hanmi Pharmaceutical, Co., Ltd And Collaborative Partner Kinex Pharmaceuticals Report Encouraging Results On Oraxol® For Patients With Advanced Gastric Cancer From A Phase I/II Clinical Study 6/30/2014
TiGenix Announces The Clinical Development Of Cx611 In Early Rheumatoid Arthritis And Severe Sepsis 6/30/2014
Basilea Pharmaceutica (BSLN.SW) Announces Start Of Phase 2a Study With Oncology Drug Candidate BAL101553 6/26/2014
Bone Therapeutics Starts Patient Treatment In First Ever Clinical Trial With Allogeneic Bone Cell Therapy Product 6/25/2014
EnGeneIC Pty Ltd Unveils Clinical Development Strategy for EDV™ Nanocell Technology 6/24/2014
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) And Oral GCD To Be Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/23/2014
VBL Therapeutics Announces Completion Of Enrollment In Phase 2 Clinical Studies Of VB-201 In Psoriasis And Ulcerative Colitis 6/20/2014
Neurim Pharmaceuticals Announces Publication Of Positive Effects Of Add-On Circadin® In Alzheimer's Disease Patients 6/19/2014
Protalix Biotherapeutics, Inc. (PLX) Initiates Phase 2 Study With PRX-112, An Orally-Administered Enzyme Replacement Therapy For The Treatment Of Gaucher Disease 6/18/2014
Celsus Therapeutics (CLTX) Receives Approval From The Ministry Of Health Of Israel For Phase 2 Trial Of MRX-6 In Pediatric Atopic Dermatitis Patients 6/17/2014
Zealand Pharma  (ZEAL.CO) Provides Summary Of New Clinical Data And Information On Lyxumia® (Lixisenatide) And Lixilan Presented At The American Diabetes Association’s 74th Scientific Sessions 6/17/2014
Senhwa Biosciences Initiates Phase 1/2 Trial Of CX-4945 In Combination With Gemcitabine And Cisplatin 6/17/2014
Grifols Completes Patient Enrollment In Its Phase2/3 Psoriasis Trial; Final Results Are Expected In Q1 2015 6/17/2014
Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy And Safety In Ground-Breaking Phase II Trigeminal Neuralgia Study 6/16/2014
ALK-Abello A/S’s Partner For Japan Announces Trial Results For House Dust Mite SLIT-Tablet 6/16/2014
Astex Pharmaceuticals (ASTX) Presents Final Results Of Phase 2 Study Of SGI-110 In Treatment Naïve Elderly Acute Myeloid Leukemia At The European Hematology Association Meeting 6/16/2014
Generex Biotechnology Corporation (GNBT)/Antigen Express, Inc. (GNBT) Announce Interview Of MD Anderson Cancer Center's Dr. Elizabeth Mittendorf, Principal Investigator On Company's AE37 Phase IIb Breast Cancer Efficacy Trial 6/12/2014
Umecrine Mood's Premenstrual Dysphoric Disorder (PMDD) Drug Fails Phase 2 Study 6/12/2014
Pfizer Inc. (PFE) To Showcase Over 10 Abstracts For XELJANZ® At Major Conference 6/11/2014
OphthaliX Inc. Provides An Update On Its Clinical Developments And Strategic Plans 6/9/2014
PsiOxus Therapeutics Limited Announces Positive Study Results Of Oncolytic Vaccine Enadenotucirev At 2014 American Society of Clinical Oncology Annual Meeting 6/3/2014
Jazz Pharmaceuticals plc (JAZZ) Presents JZP-110 Phase 2b Data For The Treatment Of EDS Symptoms In Adults With Narcolepsy 6/3/2014
Novartis AG (NVS)'s Drug Zykadia™ Shrank Tumors In Phase 1 Study 6/3/2014
Can-Fite BioPharma (CFBI) Announces That The FDA Has Agreed With Its Phase 2 Liver Cancer Protocol 6/2/2014
NOXXON Pharma AG’s Emapticap Pegol Study Selected For Late Breaking Clinical Trials Symposium During ERA-EDTA Conference 6/2/2014
D-Pharm Ltd. Reports Completion Of The Second Dose Tier In Its Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With The Thrombolytic Drug tPA 6/2/2014
BioTie Therapies Corp.: Nepicastat Study In Cocaine Dependence Completes Enrollment Ahead Of Schedule - Top-Line Data Expected Around End 2014 5/27/2014
TRANSGENE (ENX:TNG) Announces Promising Results In An Update From The Phase 2b Part Of TIME Trial With TG4010 In Advanced Non-Small Cell Lung Cancer 5/27/2014
Edison Pharmaceuticals, Inc.'s EPI-743 Granted Orphan Designation For Leigh Syndrome In Japan 5/21/2014
MediWound (MDWD) Initiates Second Phase 2 Clinical Trial Of Escharex™ To Treat Chronic And Other Hard-To-Heal Wounds 5/21/2014
MorphoSys AG's MOR208 Program To Receive Orphan Drug Designation From FDA And European Medicines Agency For The Treatment Of CLL/SLL 5/20/2014
Sanofi Pasteur (SASY.PA) Announces Favorable Phase 2 Study Results For Investigational Clostridium difficile Vaccine At The American Society for Microbiology Meeting 5/19/2014
Juventas Therapeutics, Inc. Data Demonstrates Significant Structural, Clinically Meaningful Benefit In Patients With Advanced Heart Failure 5/19/2014
Pluristem Therapeutics (PSTI) Receives Clearance From South Korea To Use PLX Cells Manufactured At Its New Facility In Its Advances Studies 5/19/2014
Kamada Ltd. (KMDA) Crashes After Key Trial Failure 5/19/2014
Telormedix' Vesimune Successfully Completes Phase 2 For Carcinoma In Situ Of The Bladder 5/16/2014
AstraZeneca PLC (AZN) Touts Success In 2 Phase 2 Studies 5/15/2014
AstraZeneca PLC (AZN) Announces Results Of Phase 2b Studies 5/13/2014
AiCuris And Merck & Co., Inc. (MRK) Announce Publication In New England Journal Of Medicine Of Phase 2 Clinical Trial Results Of Investigational Antiviral Agent Letermovir In Bone Marrow Transplant Patients 5/8/2014
Alcobra (ADHD) Announces FDA Clearance Of Protocol For Phase 2b Study Of Metadoxine Extended Release (MDX) In The Treatment Of Fragile X Syndrome 5/8/2014
Biota Pharmaceuticals, Inc. Provides An Update On The Development Of Laninamivir Octanoate 5/1/2014
Can-Fite BioPharma (CFBI) Submits Protocol To FDA For Phase II Liver Cancer Study 4/29/2014
Bavarian Nordic (BAVA.CO) Announces First Patient Treated In A Phase 2 Study Evaluating Its Immunotherapy Candidate CV-301 In Bladder Cancer 4/28/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Scientific Publication Of Phase 2 Study Demonstrating Conversion From Twice-Daily Tacrolimus To Once-Daily Envarsus® In Liver Transplant Patients 4/28/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Scientific Publication Of Phase 2 Study Demonstrating Conversion From Twice-Daily Tacrolimus To Once-Daily Envarsus® In Liver Transplant Patients 4/28/2014
Prima Biomed (PRR.AX)'s CAN-004 Phase 2 Trial For Cvac™ Commences Recruitment 4/28/2014
FDA Approves Commencement Of BrainStorm Cell Therapeutics Inc.'s Phase 2 ALS Clinical Trial In U.S. 4/28/2014
Kamada Ltd. (KMDA.TA) Announces Significantly Improved Infusion Rate For Glassia® 4/24/2014
Teva Pharmaceutical Industries Limited (TEVA) Release: Pride-HD Study Enrolling Patients Globally To Further Evaluate Pridopidine For The Symptomatic Treatment Of Huntington’s Disease 4/24/2014
Anergis Completes Enrolment In The Long-Term Efficacy Trial Of Lead Compound AllerT 4/23/2014
Galapagos NV (GLPG.BR) Release: GSK2586184 Met Primary Endpoint In Phase 2a Psoriasis Study 4/17/2014
Final Data From The Phase 2 COSMOS Study Of Janssen Research & Development's Once-Daily Simeprevir In Combination With Sofosbuvir Presented At The International Liver Congress™ 2014 Of The European Association For The Study Of The Liver (EASL) 4/14/2014
Cytos Biotechnology AG's Asthma Drug CYT003 Flunks Pivotal Phase 2b Study 4/14/2014
GenKyoTex S.A. 's GKT137831 Found To Reverse Fibrosis And Improve Survival In A Model Of Persistent Lung Fibrosis 4/10/2014
Gilead Sciences, Inc. (GILD) Announces Phase 2 Results For Two Investigational All-Oral Sofosbuvir-Based Regimens For The Treatment Of Chronic Hepatitis C 4/10/2014
BioLineRx Ltd. Announces Investigator-Initiated Study For Novel Chronic Myeloid Leukemia Treatment 4/10/2014
Alcobra (ADHD) Submits Protocol To FDA For Phase 2b Clinical Study Of Metadoxine Extended Release (MDX) In The Treatment Of Fragile X Syndrome 4/10/2014
Adocia Reports Positive Results From Phase 2a Clinical Study Of Ultra-Fast Acting Biochaperone® Lispro 4/9/2014
NOXXON Pharma AG Release: Anti-Hepcidin Spiegelmer® Lexaptepid Pegol Increases Hemoglobin In Subset Of Anemic Patients In Pilot Phase 2a Study 4/8/2014
Mologen AG (MOLGF.PK): DSLIM® Shows Superior Immunoactivation Capabilities 4/8/2014
Viralytics Ltd (VLA.AX) Release: Positive Interim Phase 2 Trial Results For CAVATAK™, Novel Cancer Immunotherapy 4/8/2014
Pfizer Inc. (PFE) Continues Its Streak, Phase 2 Breast Cancer Results Wows Investors And Researchers 4/8/2014
Alnylam Pharmaceuticals (ALNY) Receives Positive Opinion For Orphan Drug Designation In The European Union For ALN-Ttrsc, A Subcutaneously Delivered Rnai Therapeutic For The Treatment Of Transthyretin-Mediated Amyloidosis (ATTR) 4/2/2014
PRANA Biotechnology (PRAN) Tanks As Lead Drug Fails Alzheimer's Study 4/1/2014
Forest Laboratories, Inc. (FRX), Gedeon Richter Ltd. (RIG2.F) Tout Positive Phase 2b Bipolar Depression Data 3/31/2014
Published Analysis Confirms Positive Results From Auris Medical AG's Phase 2b Study With AM-101 In Treatment Of Acute Inner Ear Tinnitus 3/31/2014
Novartis AG (NVS)'s Rare Lung Cancer Drug Ceritinib Shows Positive Response In Study 3/27/2014
Forest Laboratories, Inc. (FRX), Gedeon Richter Ltd. (RIG2.F) Shows Off Positive Phase 2b Data For Cariprazine To Treat Depression 3/21/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1103 Acromegaly Phase 2 Trial Recruitment Completed 3/21/2014
Bionomics Limited (BNO.AX) Sinks As Renal Cancer Drug Fails Key Phase 2 Test 3/19/2014
Ipsen (IPN.PA): Dysport Incontinence Treatment Phase 2a Trial Positive 3/18/2014
Pharma Two B Ltd. Commences Phase 2b Study Of Fixed Dose Combination Therapy “P2B001” For Parkinson’s Disease 3/18/2014
Asthma Leader GlaxoSmithKline (GSK) Faces Competition From Roche (RHHBY), AstraZeneca PLC (AZN), Sanofi (France) (SAN.PA), And Teva Pharmaceutical Industries Limited (TEVA) 3/18/2014



//-->